Filing summary
Entity and period: The filing is ZIOPHARM Oncology, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2013. This differs from the request metadata naming Alaunos Therapeutics, Inc.; verify the issuer and filing before relying on this summary.
Business context and reporting period
ZIOPHARM was a development-stage biopharmaceutical company focused on cancer therapies. It had no approved products and had generated no product sales. Its principal development focus was Intrexon-partnered synthetic biology, led by Ad-RTS-IL-12; it was seeking partners for small-molecule candidates.
Financial results and liquidity
| Metric | Q3 2013 | Nine months 2013 | Comparable 2012 period |
|---|---|---|---|
| Revenue | $0.2 million | $0.6 million | $0.2 million / $0.6 million |
| Research and development | $6.2 million | $40.1 million | $16.2 million / $48.5 million |
| General and administrative | $3.1 million | $11.5 million | $5.7 million / $15.5 million |
| Net loss | $16.7 million | $48.2 million | $17.8 million / $65.9 million |
| Net loss per share | $0.20 | $0.58 | $0.23 / $0.85 |
| Operating cash used | Not stated for quarter | $50.5 million | $57.3 million |
Revenue was collaboration revenue recognized from Solasia research funding, not product sales. The nine-month loss improvement reflected lower operating costs, partly offset by warrant fair-value changes. Q3 included a $7.4 million warrant fair-value loss, versus a $3.9 million gain in Q3 2012; for the nine-month period, the warrant item was a $3.0 million gain versus a $2.5 million loss in 2012. These noncash valuation changes made reported earnings volatile. Operating margins are not meaningful given minimal collaboration revenue and ongoing development spending.
Cash and cash equivalents were $23.6 million at September 30, 2013, down from $73.3 million at year-end 2012. Working capital was $13.9 million, down from $61.4 million. Total assets were $29.5 million, liabilities $25.8 million, and stockholders’ equity $3.6 million. The balance sheet reports a $10.0 million warrant liability and deferred revenue; it does not identify conventional borrowings. Nine-month financing cash flow was $0.9 million, versus $49.4 million in 2012, when the company raised substantial equity capital. Contractual obligations totaled $6.4 million, including operating leases, license/royalty fees, and contract milestones.
Material changes versus the prior comparable period
- Management terminated palifosfamide development in first-line metastatic soft tissue sarcoma after the Phase 3 PICASSO 3 trial missed its primary endpoint. Enrollment in the Phase 3 small-cell lung cancer MATISSE trial was suspended pending further data.
- A cost-reduction plan eliminated 40 filled positions and 25 unfilled positions. Lower clinical, manufacturing, personnel, and other costs reduced R&D; workforce reductions also lowered G&A.
- Nine-month R&D expense declined 17% and G&A declined 26% year over year. Operating cash use decreased by $6.8 million, while cash fell substantially as prior-year financing did not recur.
- In August, the company subleased part of its Boston office but remained liable under the original lease; it recorded a $42,000 sublease loss and a $194,000 asset-disposal loss.
Outlook, commentary, and risks
- Management expected cash to fund operations into the first quarter of 2014. It stated that additional financing would be needed for longer-term clinical and product-development plans and that there were no committed sources of additional capital.
- The filing reports that the independent registered public accounting firm expressed substantial doubt about the company’s ability to continue as a going concern. Management warned that unavailable or unacceptable financing could force delays, reductions, or termination of programs.
- Ad-RTS-IL-12 was in Phase 2 studies for melanoma and metastatic breast cancer. Management expected preliminary data from these studies in Q4 2013 and final data in 2014. It planned additional studies, including a glioblastoma Phase 1 and melanoma and breast-cancer combination studies, with targeted starts in Q1 2014; these were forward-looking plans, not assured outcomes.
- Management planned at least eight IND applications through 2015. MATISSE interim overall-survival analysis was forecast for the first half of 2014. These timelines and plans depended on funding, trial execution, and regulatory developments.
- Clinical and preclinical development, regulatory approval, manufacturing capacity, and the novel synthetic-biology platform carry significant execution and cost risks. The Intrexon agreement includes a 50% share of product net profits or certain sublicense revenue, and the company’s rights may be affected by termination provisions.
- The filing reported no material legal proceeding as of September 30, 2013 and no material subsequent event through filing. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that ZIOPHARM Oncology, Inc.—not Alaunos Therapeutics, Inc.—is the intended issuer and that the filing period is correct.
- Check subsequent financing, cash runway, and any later going-concern disclosures; the stated runway ended in Q1 2014.
- Verify actual results and timing for the melanoma and breast-cancer trials, planned combination studies, glioblastoma study, and MATISSE interim analysis.
- Review the full filing and subsequent disclosures for warrant terms and fair-value effects, Intrexon-related obligations, and the status of palifosfamide programs.